BioSpace News Archive

Journey Medical Corporation announced financial results and recent corporate highlights for the first quarter ended March 31, 2022.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company designing and developing novel targeted therapies for cancer treatment, today reported financial results for the quarter ended March 31, 2022 and provided operational updates.

Amicus Therapeutics announced that the U.S. Food and Drug Administration has extended the review period by 90 days for the Biologics License Application for cipaglucosidase alfa and the New Drug Application for miglustat, the two components of AT-GAA.

Sera Prognostics Inc., The Pregnancy Company®, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced financial results for the first quarter ended March 31, 2022.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today reported financial results for the first quarter of 2022 and provided an update on recent corporate progress.

INOVIO reported financial results for the quarter ended March 31, 2022 and announced recent program and corporate developments.

INOVIO announced the appointment of Jacqueline Shea, Ph.D., as President and Chief Executive Officer of INOVIO, effective immediately.

AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2022.

Rockley Photonics Holdings Limited (NYSE: RKLY) (“Rockley”), a global leader in photonics-based health monitoring and communications solutions, today announced that the company has successfully completed its preliminary human study measuring hydration levels using Rockley’s non-invasive biomarker sensing platform.

BostonGene Announces Integration With NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ),